New membrane could speed healing of eye infections
NCT ID NCT07559149
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding a special amniotic membrane containing riboflavin and moxifloxacin to standard PACK-CXL therapy helps heal infected corneal ulcers faster. 32 adults with moderate-to-severe ulcers took part. The goal was to see if the membrane improves corneal healing and reduces inflammation compared to standard treatment alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- amniotic membrane containing riboflavin and moxifloxacin
- What this could lead to
- If it works, this could offer a better way to treat infected corneal ulcers, speeding up healing and reducing inflammation.
- What could go wrong
- This is a small, early-phase trial with only 32 participants. The results may not apply to all patients, and the added membrane might not improve outcomes over standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CXL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dr. Sardjito General Hospital
Sleman, Special Region of Yogyakarta, 55281, Indonesia